Cell Motion Laboratories, Incorporated – Trademark Portfolio

Entity Type: 99

Cell Motion Laboratories, Incorporated holds 2 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 41 (Education & Entertainment) — 2 filings in this category. Currently, 2 trademarks are registered. Notable registered marks include BIOBUS and BIOBASE. The owner is based in New York, NY.

P.O. box 20374

New York, NY 100098960

2 Total Trademarks

Add to watchlist:

No watchlists yet
Loading...
By Date
By Name
Filter by Class:

BIOBUS
BIOBUS
Registered 2015
BIOBASE
BIOBASE
Registered 2015

Trademark Classifications

Cell Motion Laboratories, Incorporated's trademark portfolio spans 1 Nice Classification class, reflecting the scope of goods and services protected under their brand portfolio.

41
Education & Entertainment (2 filings)

Education; providing of training; entertainment; sporting and cultural activities

Frequently Asked Questions

How many trademarks does Cell Motion Laboratories, Incorporated have?

Cell Motion Laboratories, Incorporated has 2 U.S. trademarks filed with the USPTO. Of these, 2 registered.

What trademark classes does Cell Motion Laboratories, Incorporated file in?

Cell Motion Laboratories, Incorporated files trademarks across 1 Nice Classification class. The most active classes are Class 41 (Education & Entertainment). Class 41 covers education; providing of training; entertainment; sporting and cultural activities.

What are Cell Motion Laboratories, Incorporated's most well-known trademarks?

Cell Motion Laboratories, Incorporated's registered trademark portfolio includes well-known marks such as BIOBUS and BIOBASE. These are among 2 currently registered trademarks in the portfolio.

What is Cell Motion Laboratories, Incorporated's trademark registration success rate?

Cell Motion Laboratories, Incorporated has a 100% trademark registration rate, with 2 out of 2 resolved applications resulting in successful registration. Currently, 0 applications are pending review.